A multi-part, adaptive, Phase 1, first time in human study in healthy participants and participants with atopic dermatitis (AD) to assess the safety, tolerability, pharmacokinetics (PK) of single ascending (SAD), multiple ascending doses (MAD) and selected dose of SYX-5219 (AD Participants)

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522216-17-00

Acronym

SYX-5219-101

Enrollment

Registered

2025-10-09

Start date

2026-01-26

Completion date

Unknown

Last updated

2026-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Bulgaria, Germany, Ireland

None listed

Source: EU CTIS · Data processed: Feb 4, 2026